Q-omics provides the consensus-scored PTH profile across patient tissues and cancer cell-line models. PTH expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, PTH is differentially expressed in 3, with the highest sampling consensus in KIRC. Additionally, PTH RNA expression shows 5,747 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight OV, KIRC, and STAD as cancer lineages where PTH shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTH — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTH survival associations across molecular data types. PTH RNA expression shows survival associations in the most cancer types (16), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTH RNA expression–survival associations across cancer types. High PTH expression shows unfavorable associations in READ, KIRC, LIHC and UCS, but favorable associations in OV and MESO. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for PTH RNA expression.
This table summarizes PTH tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PTH. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTH shows lower tumor expression in STAD and higher tumor expression in KIRC and HNSC. The KIRC box plot shows higher PTH RNA expression in tumor versus normal tissue (log2 FC = +0.053, t-test p = .004).
This table shows molecular features associated with PTH in patient tissues and cancer cell lines. In patient samples, PTH shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PTH RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SKIN.
